Skip to main content
Download PDF

Establishment of an optimized orthotopic bladder cancer model in mice

BMC Urology volume 22, Article number: 142 (2022) Cite this article

Abstract

Background

Bladder cancer (BC) is one of the most common malignancies of the genitourinary system. Animal models offer an important tool to explore tumour initiation, progression, and therapeutic mechanisms. Our aim is to construct an optimized orthotopic BC model which is predictable, reproducible, and convenient.

Methods

The optimized orthotopic BC model was constructed in male C57BL/6 mice utilizing microsyringes to inoculate them with a murine BC cell line (MB49). Anesthetised mice were inoculated with an MB49 cell suspension (10 µL) at approximately 5 × 106/mL. The whole process of modelling was observed and monitored every 3 days for 21 days utilizing HE staining and transabdominal ultrasonography (TUS).

Results

In this study, the model showed excellent success rates for tumour formation (96.67%) and metastatic rate (89.66%). Compared to the control group (sham operation), mice in the modelling group had serous cachexia, visible haematuresis and weight loss (all P < 0.05). The lungs, liver, ureter and kidneys were found to have tumour metastasis. Moreover, the average survival time (19.73 ± 1.69 d) of modelling mice was significantly shorter than that of the control mice (P < 0.05), which remained alive.

Conclusion

Our study established a method using microsyringes to inject murine BC cells into the bladder wall, creating a stable transplantable BC model in mice.

Peer Review reports

Introduction

Bladder cancer (BC) is one of the most common urogenital malignancies, which threatens human health for many years. The global incidence of BC ranks tenth, with up to 573,278 cases in 2021 [1]. According to the clinical pathological classification, bladder urothelial carcinoma accounts for 90–95% of BC cases, and the rest are bladder adenocarcinomas and squamous cell carcinomas [2]. Approximately 75% of BCs are classified as pure urothelial carcinomas, and the remaining 25% are urothelial and nonurothelial tissues [3]. BC can be classified into either muscle invasive BC (MIBC) or non-muscle invasive BC (NMIBC). The proportion of NMIBC is 70% in the first diagnosed, based on the depth of invasion of the bladder wall. For MIBC with nonmetastatic disease, the 5-year overall survival rate is 36%-48%, while the 5-year overall survival rate in MIBC with distant metastasis and regional metastasis is 5% and 36%, respectively [4]. Patients with BC have variable prognoses due to different clinical characteristics and pathological classifications. Current standard therapy for NMIBC is transurethral resection of the bladder tumour (TURBT), and subsequently, the implementation of various chemotherapies. Radical cystectomy depends on whether BC metastasizes to MIBC, and then chemotherapy, immunotherapy, and targeted therapy are performed [4]. Despite many advances in BC diagnosis and therapy, a high rate of metastasis, drug resistance and tumour recurrence, resulting from remarkable genomic instability and high intratumor heterogeneity remain to be overcome [5, 6]. A proper orthotopic animal model that is reproducible, reliable, and simple plays an important role in studying the mechanism of BC.

A murine BC model has many controllable variables under laboratory conditions, offering many experimental parameters [7]. Previous studies indicate that the ideal BC animal model is described as follows: (1) it occurs in the bladder; (2) it allows tumours to originate from urothelial cell carcinoma; (3) it grows via an immunocompetent host; and (4) it is operationally easy to reproduce [8].

In this study, we reported an improved orthotopic BC model established with microsyringes in mice. Our aim was to provide a stable, reproducible, convenient method for constructing a murine BC model in male mice. Meanwhile, the model can offer a useful tool for studying the growth, invasion, metastasis, drug resistance and therapy of tumours.

Methods

Chemicals and equipment

Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered saline (PBS), foetal bovine serum (FBS), trypsin and penicillin–streptomycin solution were obtained from Gibco (Gibco, USA). Depilatory cream was purchased from Veet (Veet, USA). Pentobarbital sodium was provided by Professor Chen She from Fudan University. Microsyringes were purchased from Hamilton (Hamilton, USA) (Fig. 1). A multi-mode ultrasound/photoacoustic imaging system for small animals was provided by the instrumental analysis centre of Shanghai Jiao Tong University.

Fig. 1
figure 1

Microsyringes in scattered (a) and assembled (b)

Full size image

Cell strain

The murine BC cell line MB49 was purchased from Shanghai Institutes for Biological Science, CAS. MB49 cells were derived from C57BL/6 mice via exposure of murine bladder urothelial cells to 7,12-dimethylbenz[a]anthracene (DMBA) for 24 h followed by long-term culture [9]. The cells were cultured in DMEM supplemented with 100 U/mL penicillin–streptomycin solution and 10% FBS at 5% CO2 and 37 ℃. The cells were digested using trypsin, washed with PBS, and then resuspended in PBS at 5 × 106/mL. Finally, the prepared cells were placed on ice.

Orthotopic transplantation operation

Mice were anaesthetized with pentobarbital sodium solution at a dose of 0.14 mL/10 g body weight. Subsequently, the lower abdomen of the mouse was gently massaged to expel the remaining urine, depilated, and disinfected. A 10 µL microsyringe was utilized to withdraw 10 µL of the suspension after it was drawn up and down through the 1 mL pipettor. The approximate abdominal area of the bladder was then identified, and the cavity was opened. The bladder was found and pulled out of the body so that the needle of the microsyringe was inserted into the vascular-enriched area of the bladder wall. Cells were gently injected into the bladder wall, and a white bump was observed. The wound was sutured with 6-0 nylon sutures layer by layer. The main procedures are shown in Fig. 2.

Fig. 2
figure 2

The operation procedures of orthotopic transplantation. a The lower abdomen area was depilated and disinfected. b The bladder was dissected and identify vascular-enriched area. c Gentle inject cells. d Observation after injection. e Close the lower abdomen and disinfect

Full size image

Animals

Our present experiments were approved by the local ethics committee and the Shanghai Medical Experimental Animal Care Commission. To establish the improved orthotopic model, six-week-old male C57BL/6 mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. Mice were fed in a pathogen-free animal facility under standard conditions. All animals were randomly assigned to either the experimental or control group. All animal operations were performed according to the criteria and principles in the “Guide for the Care and Use of Laboratory Animals” published by the National Academy of Sciences and prepared by the National Institutes of Health (NIH Publication 86-23 revised 1985).

HE staining

Specimens collected after BC included bilateral ureters, liver, kidneys, heart, spleen and lungs. They were washed with PBS, fixed in formalin for 24 h, dehydrated with 70%, 80%, 90% ethanol and absolute alcohol for 5 h, and then vitrified with xylene I and xylene II for 20 min. The specimens were embedded and sliced after immersing in paraffin I and II for 1 h. Staining was completed as follows: haematoxylin staining for 10 min, hydrochloric acid alcohol solution for 20 s destaining, eosin staining for 2 min and 90% ethanol for 40 s destaining. Finally, the section was mounted with neutral balsam and observed and photographed under a microscope [10].

Statistical analysis

If data did not conform to a normal distribution, the Mann–Whitney test was used. Statistical analysis between groups for significance was completed using Student’s t-test. The results were analysed using GraphPad 8.0 software. The results of the analysis are presented as the mean value ± SD. The level of significance in the statistics was set at *P < 0.05; ** P < 0.01; ***P < 0.001.

Results

The evaluation of tumour progression

In our study, a total of 30 C57BL/6 mice in the modelling group were injected with a 10 µL suspension in the bladder wall. Mice in the control group underwent sham surgery under the same conditions. Murine haematuresis was observed on the 17th day, as shown in Fig. 3a. The whole observation was suspended on the 21st day. Then, murine abdominal organs were exposed, and no typical peritoneal metastasis was found (Fig. 3b).

Fig. 3
figure 3

Exhibition of murine hematuresis (a) and abdominal organs (b)

Full size image

Furthermore, with the help of transabdominal ultrasonography (TUS), the growth process of bladder tumours was detected every 3 days from the first day to the last day in both groups. Meanwhile, the liver was monitored during the observation of bladder tumours due to the excellent performance of TUS. The visible tumours were detected on the 13th day, and the larger tumours were monitored in later observations on the 17th and 21st days (Fig. 4a). No significant difference was observed from the imaging data, as shown in Fig. 4b.

Fig. 4
figure 4

TUS of a mouse bladder tumor and liver. a The growth of bladder tumor can be observed and measured longitudinally via TUS. b The liver can be monitored by TUS during the observation of bladder tumor

Full size image

The analysis of survival time

Mice began to die on the 16th day in the modelling group following cell inoculation. Half of the mice in both groups died, which denoted the end of the experiment. The remaining mice were sacrificed after the experiment was completed. There were 29 C57BL/6 mice with tumours in the modelling group, while tumours did not occur in mice that received a sham operation. The tumour incidence was 96.67%. The average survival time in the modelling mice was (19.73 ± 1.69 d) (Table 1). The average survival time in the modelling mice was distinctly lower than that in the control group (P < 0.0001), which is displayed in Fig. 5.

Table 1 Tumor incidence, average survival time, average bladder wet weight, average mouse weight and tumor volume
Full size table
Fig. 5
figure 5

Survival time of the modelling and the sham operation

Full size image

Metastasis in the modelling group

As the picture shows (Fig. 2c), a white bump was formed by resuspended cells. Meanwhile, vascular wall was intact. And the needle did not break through vascellum so that the injected cells did not go directly into the systemic circulatory system. With the help of invasive characteristic of tumour cells, tumour progression and metastasis happened in that context. There were 26 C57BL/6 mice that were observed to have metastasis (Fig. 6d), which was found in the lungs (23/26), liver (22/26), ureter (11/26) and kidneys (5/26) (Fig. 6d). The metastasis rate of all mice was 89.66%. A total of 4 organs (lungs, liver, ureter, kidneys) were observed to have metastasis (Fig. 8b, c, f, g), while the spleen and heart were not found to have metastasis (Fig. 8a, d). The metastatic rate of the lungs, liver, ureter and kidneys was calculated as 88.46%, 84.62%, 42.31% and 19.23% of the metastatic mice in the modelling group, respectively (Fig. 6c), and the proportion of metastasis in the lungs, liver, ureter, and kidneys in nonmetastatic mice accounted for 79.31%, 75.86%, 37.93%, 17.24% and 10.34% in the modelling group, respectively (Fig. 6c).

Fig. 6
figure 6

Comparison of average bladder wet weight (a) and average mouse weight (b) and metastasis analysis (c, d)

Full size image

The assessment of pathology

An intact, smooth bladder mucosa was observed via HE staining and TUS in the sham operation group (Fig. 7a, c). Bladder tumours in the modelling group were confirmed via HE staining (Fig. 7b), while mice that underwent the sham operation had normal bladders (Fig. 7a). The TUS image showed the same result (Fig. 7c). There was no distinct difference between the two groups (Fig. 7d), and the liver in the control group was not found to have cancerous nodes via HE staining (Fig. 7e). No metastases were detected by the same method in other abdominal organs. Compared with the control group, the modelling mice had serous cachexy and visible haematuresis. The mouse weight data of both groups were analysed, which indicated that the weights in the control group were significantly higher those in the modelling group (P = 0.0108) (Fig. 6b). The average weight in the modelling mice was 27.40 ± 0.82 g; on the other hand, the average weight in the control mice was 28.06 ± 1.07 g. Subsequently, each bladder in the two groups was weighed, and the results showed that the average wet bladder weight in the modelling mice (0.0385 ± 0.0048 g) was significantly higher than that in the control mice (0.0345 ± 0.0056 g) (P = 0.0048) (Fig. 6a, Table 1). The average tumour volume was calculated to be 2.58 ± 2.50 mm3 (Table 1).

Fig. 7
figure 7

Pathological images and TUS of mice bladder and liver in the control and modelling group. a, b Pathological images (HE staining) of bladder tumor in the control group (sham operation) and the modelling group. c, d Bladder and liver of TUS of bladder tumor in the control group (sham operation) and the modelling group. e Pathological images (HE staining) of liver in the control group

Full size image

Tumour cells infiltrated deeply into the muscular layer, which shows typical cellular atypia (Fig. 8e). Interestingly, tumour morphogenesis of cellular shape and disordered arrangement indicate the loss of cell polarity (Figs. 5b, 8e). Some tumour slices were observed to have normal urothelium. Furthermore, perimeter cells of low-grade bladder tumours had the characteristics of a slightly rounded and relaxed overall surface with a more regular arrangement (Fig. 8e). The high-grade internal tumour cells have a twisted and crowded shape with a nucleus that has an irregular appearance. A large number of cells in the central part of the tumour exhibited necrosis due to the lack of blood supply (Fig. 5b). All pathological results from tumour-bearing mice were confirmed to be MIBC by two attending urologists.

Fig. 8
figure 8

Pathological images of spleen (a), lung (b), liver (c), heart (d), bladder (e), ureter (f), kidney (g)

Full size image

Discussion

Given the global incidence and mortality of BC, research on BC is very important. The orthotopic murine transplantable model of BC is a practical model which takes into account the clinical pathological analogy to humans [11]. Murine orthotopic BC models can be divided into two groups: (1) nonautochthonous models and (2) autochthonous models. Nonautochthonous models often utilize orthotopic engraftment in which murine syngeneic or human BC cells adhere to the bladder wall of normal or immunodeficient recipient hosts. Moreover, BC cells can also be injected into the wall of the bladder, which plays the same role as orthotopic engraftment, allowing tumours to grow in the bladder [12,13,14,15,16,17]. Autochthonous models consist of orthotopic carcinogen-based models and transgenic or genetically engineered mice (GEMs). The first orthotopic BC model was induced with carcinogens in rats, and the most common carcinogen used to induce BC in mice is N-butyl-N-[4-hydroxybutyl] nitrosamine (BBN) [18,19,20]. Transgenic mice or GEM orthotopic models are generated to either carry cloned oncogenes or lack tumour suppressing genes, including the Cre-loxP system and the injection of adenovirus-Cre in the lumen of the bladder [21,22,23,24]. As demonstrated above, there are four most frequently used methods to construct orthotopic murine models of BC. First, a tumour cell suspension is instilled into the bladder via catheter or laparotomy [25, 26], which utilizes N-methyl-N-nitrosourea or a mixture of chlorhydric acid and potassium hydroxide [8, 27, 28]. This method does not lead to urinary stones or traumatic ulceration, and its rate of tumour implantation ranges from 28 to 100%. The tumour occurrence is multifocal and unpredictable in localization. Moreover, operations are invisible because the process occurs inside the bladder so that the success rate is unreliable. Second, weak acid, protease or other chemicals are injected into the bladder mucosa for corrosion before tumour cells are injected [29,30,31]. This method requires complicated experimental conditions, such as corrosion time, and the tumour-bearing rate is unstable. The third method utilizes mechanical tools to injure the bladder mucosa before tumour cells are injected via inserting a stylet or other tools [32]. All operations happen inside the bladder so that the process is uncontrolled and the success rate is uncertain. The fourth method resembles our operation, in that it uses a regular injector to inoculate mice. However, the volume of the cell suspension cannot be controlled. Abdominal metastasis happens unpredictably, resulting in the obstruction of experimental conclusions or the addition of interference factors [33,34,35,36,37].

Transabdominal operation is one of the most controlled methods of constructing a murine orthotopic model in which the procedures are visible. And different pathological types have an impact on clinical outcomes, such as non-urothelial variant histology (VH) bladder cancer (BC) and urothelial carcinoma of the urinary bladder (UCUB) [38]. Despite the technical difficulty of orthotopic tumour cell transplantation, this method improves the tumour-bearing rate and avoids pathological variants. Intravesicular instillation of tumour cell suspensions via catheters or stylets is currently one of the most frequent methods used to establish orthotopic murine models of BC with or without injury. Interestingly, female mice can only be used because of anatomical features [39, 40]. Our hormone research results indicate that the level of oestrogen has a significant impact on the progression of BC (unpublished data). Although the metastatic organs did not have typical cancerous nodes, tiny cancerous nodes were found under the microscope. Previous studies of the association between oestrogen and BC have demonstrated some mechanisms [41, 42]. Moreover, the epidemiology of BC and related mechanical studies have confirmed the phenomenon and mechanism [43,44,45,46]. Our previous study found that the loss of cell polarity has an effect on tumour metastasis in BC [47], which is consistent with our present results that show that the optimized orthotopic model has a high metastatic rate. Therefore, the orthotopic BC model in our study is theoretically practical to figure out the clinical pathological process in humans. By analogy, the optimized model can be utilized in immunodeficient mice and even rats, and can be constructed under the specific conditions of human BC cells.

Conclusion

Herein, we describe a new murine orthotopic BC model that is reproducible. The model has had a major impact on helping us improve our knowledge of the mechanisms and pathogenesis of BC at the proper anatomical site. In conclusion, we succeeded to establish an improved murine orthotopic BC model derived from MB49 cells using a microsyringe. The model offers a reproducible, rapid, convenient tool to carefully study the events in multistep cascades of tumour initiation, progression, therapy and so on.

Availability of data and materials

The datasets used during the current study available from the corresponding author on request.

Abbreviations

BC:

Bladder cancer

TUS:

Transabdominal ultrasonography

GEM:

Genetically engineered mice

BBN:

N-butyl-N-(4-hydroxybutyl) nitrosamine

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  2. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.

    Article  PubMed  Google Scholar 

  3. Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020;6(4):653–63.

    Article  PubMed  Google Scholar 

  4. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980–91.

    Article  CAS  PubMed  Google Scholar 

  5. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75.

    Article  CAS  PubMed  Google Scholar 

  6. Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.

    Article  PubMed  Google Scholar 

  7. Ratliff TL. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin. Clin Infect Dis. 2000;31(Suppl 3):S106–8.

    Article  CAS  PubMed  Google Scholar 

  8. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 1999;81(4):638–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 1979;62(4):1017–23.

    CAS  PubMed  Google Scholar 

  10. Chen Z, Tao Z-Z, Chen S-M, Chen C, Li F, Xiao B-K. Indole-3-carbinol inhibits nasopharyngeal carcinoma growth through cell cycle arrest in vivo and in vitro. PLoS ONE. 2013;8(12):e82288.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009;104(9):1286–91.

    Article  PubMed  Google Scholar 

  12. Chade DC, Andrade PM, Borra RC, Leite KR, Andrade E, Villanova FE, et al. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol. 2008;34(2):220–9.

    Article  PubMed  Google Scholar 

  13. Lodillinsky C, Rodriguez V, Vauthay L, Sandes E, Casabé A, Eiján AM. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol. 2009;182(2):749–55.

    Article  CAS  PubMed  Google Scholar 

  14. Reis LO, Ferreira U, Billis A, Cagnon VHA, Fávaro WJ. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 2012;187(2):438–45.

    Article  CAS  PubMed  Google Scholar 

  15. Miyazaki J, Nishiyama H, Yano I, Nakaya A, Kohama H, Kawai K, et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res. 2011;31(6):2065–71.

    CAS  PubMed  Google Scholar 

  16. Shen Z-J, Wang Y, Ding G-Q, Pan C-W, Zheng R-M. Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol. 2007;25(5):525–9.

    Article  CAS  PubMed  Google Scholar 

  17. Black PC, Dinney CPN. Bladder cancer angiogenesis and metastasis–translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26(3–4):623–34.

    Article  PubMed  Google Scholar 

  18. Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, Mennel HD, Stahl KW. Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-nitrosamine. Z Krebsforsch. 1964;66:280–90.

    Article  CAS  PubMed  Google Scholar 

  19. Fukushima S, Hirose M, Tsuda H, Shirai T, Hirao K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gan. 1976;67(1):81–90.

    CAS  PubMed  Google Scholar 

  20. Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (New York, NY). 2008;10(8):838–46.

    Article  CAS  Google Scholar 

  21. Lin JH, Zhao H, Sun TT. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA. 1995;92(3):679–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2(12):1008–14.

    Article  CAS  PubMed Central  Google Scholar 

  23. Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, et al. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS ONE. 2013;8(9): e74809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15(1):42–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J Urol. 2012;187(3):1071–9.

    Article  CAS  PubMed  Google Scholar 

  26. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 1995;154(4):1532–8.

    Article  CAS  PubMed  Google Scholar 

  27. Soloway MS. Intravesical and systemic chemotherapy of murine bladder cancer. Can Res. 1977;37(8 Pt 2):2918–29.

    CAS  Google Scholar 

  28. Chin J, Kadhim S, Garcia B, Kim YS, Karlik S. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol. 1991;145(6):1297–301.

    Article  CAS  PubMed  Google Scholar 

  29. Oshinsky GS, Chen Y, Jarrett T, Anderson AE, Weiss GH. A model of bladder tumor xenografts in the nude rat. J Urol. 1995;154(5):1925–9.

    Article  CAS  PubMed  Google Scholar 

  30. Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LCC, Andrade E, et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res. 2008;27:78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Chan ESY, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol. 2009;182(6):2926–31.

    Article  PubMed  Google Scholar 

  32. Bisson J-F, Parache RM, Droulle P, Notter D, Vigneron C, Guillemin F. A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer. 2002;102(3):280–5.

    Article  CAS  PubMed  Google Scholar 

  33. Jiang F, Zhou XM. A model of orthotopic murine bladder (MBT-2) tumor implants. Urol Res. 1997;25(3):179–82.

    Article  CAS  PubMed  Google Scholar 

  34. Bachor R, Flotte TJ, Scholz M, Dretler S, Hasan T. Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. J Urol. 1992;147(5):1404–10.

    Article  CAS  PubMed  Google Scholar 

  35. Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol. 1991;145(2):279–83.

    Article  CAS  PubMed  Google Scholar 

  36. Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, Elhilali M. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Can Res. 1983;43(2):617–22.

    CAS  Google Scholar 

  37. Bonney WW, Henstorf JE, Emaus SP, Lubaroff DM, Feldbush TL. Immunostimulation by cryosurgery: an orthotopic model of prostate and bladder cancer in the rat. Natl Cancer Inst Monogr. 1978;49:375–81.

    Google Scholar 

  38. Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, Tian Z, Becker A, Kluth L, Roos FC, et al. Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer. 2021;19(1):60–8.

    Article  PubMed  Google Scholar 

  39. Erman A, Kamenšek U, Dragin Jerman U, Pavlin M, Čemažar M, Veranič P, et al. How cancer cells invade bladder epithelium and form tumors: the mouse bladder tumor model as a model of tumor recurrence in patients. Int J Mol Sci. 2021;22(12):6328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Morillon YM, Su Z, Schlom J, Greiner JW. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. J Immunother Cancer. 2019;7(1):150.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras AS, et al. Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer. Am J Cancer Res. 2020;10(8):2523–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Bernardo C, Monteiro FL, Direito I, Amado F, Afreixo V, Santos LL, et al. Association between estrogen receptors and GATA3 in bladder cancer: a systematic review and meta-analysis of their clinicopathological significance. Front Endocrinol (Lausanne). 2021;12: 684140.

    Article  PubMed Central  Google Scholar 

  43. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–10.

    Article  PubMed  Google Scholar 

  44. Bilski K, Dobruch J, Kozikowski M, Skrzypczyk MA, Oszczudłowski M, Ostrowski J. Urobiome in gender-related diversities of bladder cancer. Int J Mol Sci. 2020;21(12):4488.

    Article  CAS  PubMed Central  Google Scholar 

  45. Martínez-Rojo E, Berumen LC, García-Alcocer G, Escobar-Cabrera J. The role of androgens and androgen receptor in human bladder cancer. Biomolecules. 2021;11(4):594.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Sottnik JL, Vanderlinden L, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, et al. Androgen receptor regulates CD44 expression in bladder cancer. Can Res. 2021;81(11):2833–46.

    Article  CAS  Google Scholar 

  47. Wang S, Cai J, Zhang S, Dong M, Zhang L, Xu Y, et al. Loss of polarity protein Par3, via transcription factor snail, promotes bladder cancer metastasis. Cancer Sci. 2021;112(7):2625–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the experimental platform from School of Basic Medical Sciences, Fudan University, Shanghai, China, and the Department of Laboratory Animal Science Fudan University.

Funding

This study was supported by the National Natural Science Foundation (92059112, 82072821 and 81972370), Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation (20SJKJGG250) and Shanghai Specialized Research Fund for Integrated Chinese and Western Medicine in General Hospitals (ZHYY-ZXYJHZX-1-201705). Bing Shen and Mingyue Tan are the fund holders.

Author information

Author notes

  1. Jinming Cai and Zhiwen Xie contributed equally to this work

Authors and Affiliations

  1. Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 85 Wujin Road, Hongkou District, Shanghai, 200080, China

    Jinming Cai, Zhiwen Xie, Yilin Yan, Zhengnan Huang, Xiangqian Cao, Chenkai Yang, Fang Zhang & Bing Shen

  2. Department of Urology, Shanghai General Hospital Affiliated to Nanjing Medical University, Shanghai, 200080, China

    Pengfei Tang & Zeyi Wang

  3. Department of Urology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, China

    Mingyue Tan

Authors
  1. Jinming Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiwen Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yilin Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhengnan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pengfei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiangqian Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zeyi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chenkai Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mingyue Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bing Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The conception and design of the study: JC, PT, XC and MT; Data collection: JC, ZH and ZX; Data analysis: ZW and CY; Provision of study materials: YY; Article writing: All authors; Administrative support: BS and FZ; All authors have read and agreed to the published vision of the manuscript. Final approval of manuscript: All authors. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Mingyue Tan, Fang Zhang or Bing Shen.

Ethics declarations

Ethical approval and consent to participate

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was performed in line with the principles of the Declaration of Helsinki (as revised in 2013). Approval was granted by the Ethics Committee of Fudan University (NO. SYXK 2020-0032). This study is in accordance with ARRIVE guidelines.

Consent for publication

Not applicable.

Competing interests

All authors declared that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cai, J., Xie, Z., Yan, Y. et al. Establishment of an optimized orthotopic bladder cancer model in mice. BMC Urol 22, 142 (2022). https://doi.org/10.1186/s12894-022-01093-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12894-022-01093-6

Keywords

BMC Urology

ISSN: 1471-2490

Contact us